The Japanese Society for Regenerative Medicine

JSRM has approximately 6000 members involved in research in a wide variety of fields in the natural sciences such as basic medicine/dentistry, clinical medicine/dentistry, tissue engineering, and cell biology, as well as fields in the humanities and in sociology such as bioethics, regulatory science, law, and medical economics. The participating members come from various domains of academia, industry, and government.The content of the representative policy proposal, the “Yokohama Declaration”, has had significant impact on the actual content of the “Act on the Safety of Regenerative Medicine” and “Pharmaceutical and Medical Devices Act” enacted in 2014 and has attracted worldwide attention as a premier approach to legal regulations. Moreover, the putting forth of such a policy proposal itself from an academic society was highly acclaimed worldwide, and in the 2014 World Stem Cell Summit, JSRM received the International Leadership Award, which was a global first for an academic society. After 2016, JSRM acquired competitive funds called “Regenerative Medicine National Consortium”from the Japan Agency for Medical Research and Development (AMED) and has since been able to utilize public funding for activities such as the support of clinical research, development of human resources, development of clinical research data systems, coordination of academia–industry translations, and interactive communication with patients/citizens, resulting in remarkable achievements including undertaking many consulting engagements in support of clinical research and conducting educational workshops for most of the nationally accredited regenerative medicine committees. In particular, development of the “Good Post-marketing Study Practice” standard compatible database and “National Regenerative Medicine Database (NRMD)” is gaining attention as another global first in the attempt to acquire real world evidence from all clinical cases of regenerative medicine and cell therapy.